Who Owns Humacyte Stock?
NASDAQ: HUMAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 26.87%
- Held by insiders
- 5.67%
- Institutional holders
- 195
- Institutions 26.9%
- Insiders 5.7%
- Public and other 67.5%
Who owns Humacyte stock?
Institutional investors own about 26.9% of Humacyte's shares, spread across 195 institutions that file 13F reports. That level of institutional ownership is relatively low, leaving more of the stock with retail investors and insiders. Insiders, including executives, directors and large founding shareholders, hold 5.67% of HUMA.
The largest institutional holders are Vanguard Capital Management LLC (3.64%), Antipodes Partners Ltd. (3.64%) and Alyeska Investment Group, L.p. (2.17%). Together, the top 10 institutions control 17.8% of shares outstanding. In their latest filings, 7 of the top 10 institutions increased their HUMA positions and 2 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of HUMA
| Institution | Shares | % Held | Change |
|---|---|---|---|
| Vanguard Capital Management LLC | 10.11M | 3.64% | +41.2% |
| Antipodes Partners Ltd. | 10.10M | 3.64% | +76.5% |
| Alyeska Investment Group, L.p. | 6.02M | 2.17% | +100.0% |
| Davidson Kempner Capital Management LP | 5.00M | 1.80% | +100.0% |
| Blackrock Inc. | 4.84M | 1.74% | -60.7% |
| Great Point Partners LLC | 3.75M | 1.35% | 0.0% |
| UBS Group AG | 2.84M | 1.02% | +2.2% |
| AQR Capital Management, LLC | 2.60M | 0.93% | +34.9% |
| Geode Capital Management, LLC | 2.19M | 0.79% | -40.3% |
| Millennium Management Llc | 1.91M | 0.69% | +1665.1% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of HUMA
| Fund | Shares | % Held |
|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 7.72M | 2.78% |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 2.12M | 0.76% |
| iShares Trust-iShares Biotechnology ETF | 1.83M | 0.66% |
| Fidelity Concord Street Trust-Fidelity Extended Market Index Fund | 942.48K | 0.34% |
| VANGUARD SCOTTSDALE FUNDS-Vanguard Russell 2000 Index Fund | 835.68K | 0.30% |
| SCHWAB STRATEGIC TRUST-Schwab U.S. Small-Cap ETF | 728.58K | 0.26% |
| Modern Capital Funds Trust-Modern Capital Tactical Income Fund | 589.58K | 0.21% |
| VANGUARD WORLD FUND-Vanguard Health Care Index Fund | 474.57K | 0.17% |
| SCHWAB CAPITAL TRUST-Schwab Total Stock Market Index Fund | 415.18K | 0.15% |
| Fidelity Concord Street Trust-Fidelity Total Market Index Fund | 302.59K | 0.11% |
Frequently asked questions
Who is the largest shareholder of Humacyte?
Vanguard Capital Management LLC is the largest institutional shareholder of HUMA, owning 3.64% of shares outstanding (10.11M shares) as of its latest 13F filing.
What percentage of Humacyte is owned by institutions?
Institutions own about 26.9% of HUMA shares and 28.5% of the public float.
How much of Humacyte do insiders own?
Insiders, such as officers and directors, own about 5.67% of HUMA shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.